Serve biotech and pharma clients in corporate and commercial strategy (pipeline & indication prioritization, US/EU market opportunity assessment, competitive intelligence, strategic positioning) and transactions advisory (partnering & licensing)

Ouragins is committed to providing healthcare professionals safe, stylish scrubs. With its proprietary Threadfusion fabric, antimicrobial copper particles are infused directly into the threads to embed antimicrobial properties directly into scrubs.

• Assist with due diligence and fundraising for firm’s SPV investment syndicate (seed and series A biotech focused)• Hosted networking events attended by students, founders, industry professionals, and venture firms in Silicon Valley

• Lead alliance management with biopharma sponsors (MSLs, site engagement managers) to manage and grow clinical trial portfolio• Develop strategy for streamlining center's process of moving clinical trials into activation, including review of clinical trial protocols

[Business Development]• Negotiated and executed academic target discovery collaborations and led alliance management • Conducted competitive intelligence and landscape analysis to guide company strategy (databases: AlphaSense, Beacon, DealForma, UpToDate)• Created investor- and executive-facing presentations• Managed an international consortium of academics and industry professionals to submit grant for CRUK Cancer Grand Challenge[Scientist]• Established patient sample acquisition strategy and processes, including biobanking implementation, to accelerate discovery of novel T cell targets and immunotherapy response biomarkers • Managed an internal team and CROs to carry out sample processing workflows, including processing primary human samples (freeze/thaw, PBMC isolation, FACS), processing yeast samples (3T-TRACE, 3T-PRIME), and creating and sequencing Illumina sequencers-compatible NGS libraries (custom libraries, bulk RNA-seq, 10X Genomics single cell gene expression and TCR repertoire RNA-seq, HLA typing) • Individually contributed and managed a team towards analyzing bulk and single cell RNA-sequencing and TCR repertoire data (programming language: R, bash; basic computing with AWS), including the development of new analysis pipelines

• Acquired $2 million in funding for preclinical development activities through the NIH Small Business Innovation Research grant• Tested TPP and conducted market research through interviewing 50 industry and academic professionals to create target customer profiles, a business development plan, and commercialization path in the NIH I-Corps program• Designed experiments, managed CROs to carry out experiments, and analyzed resulting data to advance company's therapeutic candidates• Delivered presentations on company strategy and scientific direction to executive team• Prepared data room and pitch deck for series A fundraising

• Led teams to complete due diligence and invest 10% of the fund on two clinical-stage public biotech companies, resulting in a 3X return• Served on the management team to steer fund direction and provided feedback to investment pitches led by other partners

• Used single-cell and bulk RNA sequencing, and flow cytometry to characterize human invariant Natural Killer T (iNKT) cell heterogeneity in healthy blood donors and allogeneic hematopoietic stem cell transplant patients, and created a classification model using iNKT cell phenotype for acute graft-versus-host disease (GVHD) and treatment outcomes• Assessed the suppressive and cytotoxic capacity of human iNKT cells with mixed lymphocyte reaction and cytotoxicity assays• Developed regulatory T (Treg) cells as a therapy for acute GVHD through optimizing cell culture and expansion protocols and genetic engineering to enhance effector function • Characterized Treg cell phenotype with flow cytometry, bulk RNA and TCR sequencing, and TSDR methylation profiling in patients enrolled in a phase 2 clinical trial – infusion of regulatory T cells with conventional T cells to reduce acute GVHD incidence and improve immune reconstitution in patients with hematologic malignancies undergoing allogeneic myeloablative hematopoietic stem cell transplantation (NCT01660607)• Created and implemented lab workflow on patient sample collection, processing, and biobanking

• Liaised with BioSci Careers staff, student leadership groups, department faculty, employers, and alumni to develop programs benefitting students’ career advancement• Managed budget and develop financial plans for the year

• Assisted research analysts and associates with creating valuation models and writing sell-side reports for MLND, TPTX, and RARE

• Assessed market opportunity and defined innovation paths for client’s product in a case competition (result: runner-up).

• Assessed market opportunity for an early-stage start-up company with a novel immuno-oncology screening platform.• Interviewed key opinion leaders and created target customer profiles for client.

• Processed mouse tissues and tumors for downstream characterization including flow cytometry and microscopy to study melanoma progression

• Synthesized a panel of small-molecule bio-orthogonal chemical reporters and assessed their ability to viably label biomolecules with cell culture, flow cytometry, and western blot• Optimized split Gaussia luciferase reporters for improved imaging of cell-cell interactions through appending dimerization domains to the split luciferases with molecular cloning